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Abstract Large bowel carcinogenesis involves accumulation
of genetic alterations leading to transformation of normal mu-
cosa into dysplasia and, lastly, adenocarcinoma. It is pertinent
to elucidate the molecular changes occurring in the pre-
neoplastic lesions to facilitate early diagnosis and treatment.
Heat shock proteins (Hsps), many of which are molecular
chaperones, are implicated in carcinogenesis, and their varia-
tions with tumor progression encourage their study as bio-
markers. There are many reports on Hsps and cancer but none
to our knowledge on their systematic quantification in pre-
neoplastic lesions of the large bowel. We performed immuno-
histochemical determinations of Hsp10, Hsp60, Hsp70, and
Hsp90 in biopsies of large bowel tubular adenomas with mod-
erate grade of dysplasia and compared to normal mucosa and
adenocarcinoma with a moderate grade of differentiation
(G2). A significant elevation of Hsp10 and Hsp60 only, i.e.,
in the absence of elevation of Hsp70 or Hsp90, in both epi-
thelium and lamina propria was found in tubular adenoma by
comparison with normal mucosa. In contrast, adenocarcinoma
was characterized by the highest levels of Hsp10 and Hsp60 in
epithelium and lamina propria, accompanied by the highest
levels of Hsp70 only in epithelium and of Hsp90 only in
lamina propria, by comparison with normal and tubular ade-
noma counterparts. Hsp10 and Hsp60 are promising bio-
markers for early diagnosis of tubular adenoma and for its
differentiation from more advanced malignant lesions.
Hsp10 and Hsp60 may be implicated in carcinogenesis from
its very early steps and, thus, are potentially convenient targets
for therapy.
Keywords Hsps . Chaperone . Large bowel . Dysplasia .
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Introduction
The carcinogenic process of large bowel consists of a multi-
step sequence in which the transformation of normal large
bowel mucosa into an invasive tumor involves the accumula-
tion of various genetic alterations (Vogelstein et al. 1988),
which are accompanied by typical histological patterns visible
under the microscope. However, it is frequently challenging
for the pathologist to determine at which step in the carcino-
genic sequence is a tissue sample from a patient. Therefore,
the search for reliable, ideally step-specific, biomarkers is
worthwhile. Some heat shock proteins (Hsps) are biomarker
candidates since they have been found to vary in quantity and
distribution during carcinogenesis (Cappello et al. 2005a;
Rappa et al. 2012; Campanella et al. 2015). In this work, we
have focused on Hsp10, Hsp60, Hsp70, and Hsp90 to exam-
ine their diagnostic value in tubular adenoma and, thereby, to
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determine their utility in assessing the prognosis of an intesti-
nal lesion not yet clearly malignant.
Many Hsps are part of the chaperoning system, a physio-
logical system that is essential for protein homeostasis
(Macario and Conway de Macario 2005). Hsps perform also
other important functions such as participation in immune
system regulation (Pockley et al. 2008), cell differentiation
(Walsh et al. 1999), gene expression (Voellmy 1994), pro-
grammed cell death (Kirchhoff et al. 2002), cellular senes-
cence (Di Felice et al. 2005), and carcinogenesis (Cappello
and Zummo 2005b; Czarnecka et al. 2006a, b). Some Hsps,
including Hsp10, Hsp60, Hsp70, and Hsp90 are constitutively
expressed in cells (Macario and Conway de Macario 2005).
The implication of Hsps in the carcinogenic process in-
cludes their participation in cell proliferation (Czarnecka
et al. 2006a), angiogenesis (Sanderson et al. 2006), invasive-
ness (Zhao et al. 2007), and induction of immune tolerance
(Calderwood et al. 2005). Several studies have shown that
elevated levels of Hsps can protect malignant cells against
apoptosis induced by therapy (Joly et al. 2010).
In the past, we studied the levels of Hsp10, Hsp60, and
Hsp90 in adenocarcinoma of human large bowel (Cappello
et al. 2005c; Rappa et al. 2014; Campanella et al. 2015). In
the present work, we focused on the immunohistochemical
levels of Hsp10, Hsp60, Hsp70, and Hsp90 in large bowel
tubular adenomas with moderate grade of dysplasia and com-
pared to normal mucosa and to adenocarcinoma with a mod-
erate grade of differentiation (G2). Our aim was to determine
if these molecules are useful as biomarkers for early diagnosis
of pre-tumoral lesions in the large bowel.
Materials and methods
Formalin-fixed paraffin-embedded tissue biopsies of human
colorectal normal mucosa, tubular adenomas with moderate
grade of dysplasia, and adenocarcinoma with a moderate
grade of differentiation (G2) (n = 60 cases for each group)
were retrieved from our histological specimens collection for
immunohistochemical analyses. The normal mucosa group
consisted of 60 subjects (40 male and 20 female; average
age 65 ± 4 years) who underwent colorectal endoscopy for
screening. These subjects did not show any pathological con-
dition (cancer, polyps, or inflammatory signs). The tubular
adenomas group consisted of 60 patients. Thirty-six (60 %)
were men and twenty-four (40 %) were women. The average
age of patients was 64.9 ± 9.4 (50–87 years). The average size
of the polyps was 0.9 ± 0.2 cm (0.5–1.4 cm); in particular, the
polyps were <1 cm in size in 31 patients and ≥1 cm in 29
patients. The polyps were located in the colon in 46 cases (18
in the right colon and 28 in the left colon) and in the rectum in
14 cases. All polyps selected were histologically tubular ade-
nomas and single for each patient. The adenocarcinoma group
consisted of 60 patients affected by colorectal adenocarcinoma,
33 (55 %) were men and 27 (45 %) were women. The average
age of patients was 65.8 ± 8.6 (49–89 years). All tumor samples
selected were histologically adenocarcinoma with moderate
grade of differentiation (G2). The tumor localization was right
colon in 20 cases, left colon in 28 cases, and rectum in 12 cases.
The tumoral staging was stage I in 18 cases, stage II in 32 cases,
and stage III in 10 cases. Studies of genetic mutation were not
performed. Sections with a thickness of 4–5 μm were obtained
from paraffin blocks of biopsies with a cutting microtome.
These sections were dewaxed in xylene for 30 min at 60 °C
and after immersion in a descending scale of alcohols,
rehydrated in distiller water at 23 °C. After deparaffination,
antigen unmasking was performed with immersion of sections
in sodium citrate buffer (pH 6) at 95 °C for 8 min and, later,
with immersion in acetone at −20 °C for 8 min. All subsequent
reactions were conducted at 23 °C. After a wash with PBS
(phosphate buffered saline pH 7.4) for 5 min, sections were
immunostained, using Histostain®-Plus 3rd Gen IHC
Detection Kit (Life Techologies, Frederik, MD, USA; Cat.
No. 85–9073), which utilizes the labeled biotin-streptavidin
methodology. The primary antibodies used were anti-human
Hsp10 (rabbit polyclonal antibody, clone FL-102, Santa Cruz
Biotechnology, Inc., Heidelberg, Germany, Europe, cat. no. Sc-
28,887, dilution 1:200), anti-human Hsp60 (mouse monoclonal
antibody, clone LK1, Sigma, St. Louis, MO, USA, Cat. No.
H4149, dilution 1:400), anti-human Hsp70/HSC70 (mouse
monoclonal antibody, clone W27, Santa Cruz Biotechnology,
Inc., Europe, Cat. No. sc-24, dilution 1:200), and anti-human
Hsp90 (mouse monoclonal antibody, clone F-8, Santa Cruz
Biotechnology, Inc., Europe, Cat. No. sc-13,119, dilution
1:200). Appropriate negative (isotype) controls were run con-
currently. Nuclear counterstaining was done using hematoxylin
(Hematoxylin aqueous formula, DAKO, Denmark, N. Cat. CS
700). Finally, the sections were observed with an optical mi-
croscope (Nikon ECLIPSENi, Nikon Instrument Europe B.V.)
connected to a digital camera (DS-Fi2, Nikon Instrument
Europe B.V.) for the immunostaining evaluation. Two inde-
pendent observers (F. C and F. R) examined the specimens
on two separate occasions and performed a quantitative anal-
ysis to determine the percentage of cells positive for Hsp10,
Hsp60, Hsp70, Hsp90 in epithelium and lamina propria of
colon mucosa and to find possible correlations between
immunopositivity of Hsps and size and anatomical location
in the tubular adenoma group and location and staging in the
adenocarcinoma group. All the observations were made at a
magnification of 400×, and the percentage of positive cells was
calculated in a high-power field (HPF) and repeated for 10
HFP. The arithmetic means of counts were used for statistical
analyses. Statistical analyses were carried out using the
GraphPad Prism 4.0 package (GraphPad Inc., San Diego,
CA, USA). One-way ANOVA analysis of variance with
Bonferroni post-hoc multiple comparisons was used to find
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significant statistical differences. All data are presented as the
means ± SD, and the threshold level of statistical significance
was set at p ≤ 0.05, as indicated in the text and in the figures.
Results
Hsp10, Hsp60, Hsp70, and Hsp90 were detected and quanti-
fied immunohistochemically in epithelial and lamina propria
in biopsies of colon normal mucosa, and tubular adenoma and
adenocarcinoma counterparts. The immunopositivity evalua-
tions are expressed as average percentage in epithelial cells
(EC) and lamina propria cells (LPC) and are reported in
Table 1 and Fig. 1; representative images are displayed in
Figs. 2 and 3. In summary, in the normal mucosa group,
Hsp10 immunopositivity was cytoplasmic in 48.5 % EC and
2.1 % LPC; Hsp60 immunopositivity was cytoplasmic and
granular in 6 % EP and 1.9 % LPC; Hsp70 immunopositivity
was cytoplasmic in 30 % EC and 3.5 % LPC; Hsp90
immunopositivity was cytoplasmic in 70 % EC and 30 %
LPC. By contrast, in the tubular adenoma group, Hsp10
immunopositivity was cytoplasmic in 67.5 % EC and 6.2 %
of LPC; Hsp60 immunopositivity was cytoplasmic and gran-
ular in 65 % EP and 5 % LPC; Hsp70 immunopositivity was
cytoplasmic in 30 % EC and 3.5 % LPC; Hsp90
immunopositivity was cytoplasmic in 75 % EC and 25 %
LPC. In the adenocarcinoma group, Hsp10 immunopositivity
was cytoplasmic in 90 % EC and 10 % LPC; Hsp60
immunopositivity was visible at cytoplasmic and membrane
levels in 95 % EP and 10 % LPC; Hsp70 immunopositivity
was cytoplasmic and sometimes also nuclear in 65 % EC and
5 % LPC; Hsp90 immunopositivity was cytoplasmic in 78 %
EC and 40 % LPC.
The data show (a) the numbers of Hsp60- and Hsp10-
positive epithelial and lamina propria cells increase gradually
throughout the carcinogenic steps from normal mucosa
through tubular adenoma with moderate dysplasia to invasive
adenocarcinoma; (b) the number of Hsp70-positive cells was
significantly higher only in the epithelium of adenocarcinoma
when compared to normal and dysplastic mucosa; no differ-
ences were detectable in the lamina propria; and (c) the num-
ber of Hsp90-positive cells was significantly higher only in
the lamina propria of adenocarcinoma than in normal and
dysplastic mucosa; no differences were detectable in the epi-
thelium. No correlation was found between Hsps immunohis-
tochemical levels and size and anatomical location of tubular
adenomas or location and staging of adenocarcinomas.
Discussion
Adenocarcinoma was characterized by the highest levels of
Hsp10 and Hsp60 in epithelium and lamina propria,
accompanied by the highest levels of Hsp70 only in epitheli-
um and of Hsp90 only in lamina propria, by comparison with
normal and tubular adenoma counterparts.
On the other hand, a significant elevation of Hsp10 and
Hsp60 only, i.e., in the absence of elevation of Hsp70 or
Hsp90, in both mucosa layers was indicative of tubular ade-
noma. The results pertaining to Hsp10 and Hsp60, which are
the first to show high levels from the beginning of the carci-
nogenic process and remain high until the last step, adenocar-
cinoma, suggest that these two chaperonins are implicated in
cancer initiation and/or progression from the very early stages.
Many reports support the idea that Hsps are implicated in the
pathogenesis and in the progression of various human neo-
plasms (Ciocca and Calderwood 2005), but the mechanisms
are not yet fully understood. Although Hsp60 and Hsp10 per-
form their canonical Bchaperoning^ functions in both prokary-
otic and eukaryotic cells (Macario and Conway de Macario
2005), they have also acquired, probably during evolution,
Bextra-chaperoning^ roles. Among these roles are some
pertaining to the mechanisms of carcinogenesis in a variety
of cancer types (Czarnecka et al. 2006a). Hsp60 and Hsp10
may play a role in promoting the growth and proliferation of
cancer cells by protecting them from apoptosis. Although
Hsp60 is a molecule with specific functions related to mito-
chondrial protein folding, working together with its co-
chaperone Hsp10 (Czarnecka et al. 2006a), the chaperonin
may interact with molecules that participate in the process of
apoptosis. For example, Hsp60 can stimulate anti-apoptotic
mechanisms involving sequestration of Bax-containing com-
plexes, survivin, and p53, thus favoring tumor cell survival
(Ghosh et al. 2008; Gupta and Knowlton 2002; Shan et al.
2003).
In cancer cells, Hsp60 is localized not only in and around
the mitochondria as in normal cells but also in the cytosol very
close to the plasma membrane and in the plasma membrane
(Campanella et al. 2015). Hsp60seems to transit from the cell
to the peritumoral environment and, in this context, might
bind to the receptors present on the surface of inflammatory
cells (such as macrophages and NK cells), leading to secretion
of cytokines essential for immune surveillance. There are re-
ports that emphasize the role of Hsp60 as a ligand of toll-like
receptor-4 (TLR-4) and, consequently, as activator of innate
and adaptive immunities (Gupta and Knowlton 2007; Ohashi
et al. 2000). The activation of TLR-4 has a key role in regu-
lation of T cell- and B cell-mediated immune responses
(Kapsenberg 2003; Pasare and Medzhitov 2005) but also par-
ticipates in the activation of the NF-κB pathway, which is
known to link chronic inflammation and tumor development
(Chow et al. 2012). The peritumoral microenvironment con-
tains innate immune cells (macrophages, dendritic cells, nat-
ural killer cells) and adaptive immune cells (T and B lympho-
cytes) that communicate with each other by means of direct
contact or cytokine and chemokine production and act to
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control and shape tumor growth. The same cancer cells con-
stantly edit and modulate the host anti-tumor immune re-
sponse, and the host immune response shapes tumor immu-
nogenicity and clonal selection. During this process, the bal-
ance between anti-tumor and tumor-promoting immunity can
be tilted in favor of tumor growth (Grivennikov et al. 2010).
Tumors can induce the recruitment of regulatory T cells and
myeloid derived suppressor cells, both that are regulatory im-
mune cells capable of inhibiting the host-protective anti-tumor
response (Ostrand-Rosenberg and Sinha 2009; Zou et al.
2006). Thus, in addition to the tumor-suppressor function rep-
resented by the elimination of nascent transformed tumor cells
(cancer immune surveillance), the tumor microenvironment
can also select immune cells that are able to facilitate tumor
growth.
These concepts ought to encourage research for elucidating
at the molecular and mechanistic levels the role of Hsp10 and
Hsp60 in carcinogenesis and, eventually, developing thera-
peutic means targeting one or both chaperonins.
In this work, we have studied the levels of Hsp10, Hsp60,
Hsp70, and Hsp90 by immunohistochemistry in biopsies of
human mucosa of large bowel taken from normal control sub-
jects (normal mucosa), pre-neoplastic lesions (tubular adeno-
ma), and invasive neoplasms (adenocarcinoma). The main
purpose was to identify markers in the adenoma that would
indicate the future of the lesion, namely if it would proceed to
carcinoma or not. The results show that Hsp10 and Hsp60
levels are higher in pre-neoplastic lesions as well as in cancer
lesions compared to normal mucosa. By contrast, Hsp70 and
Hsp90 levels were increased only in the final stages, i.e., ad-
enocarcinoma, while there was no difference between normal
and pre-neoplastic lesions for these two chaperones. Hsp70
levels were higher only in the epithelial cells of the cancerous
tissue than in the tubular adenomas and normal mucosa.
Hsp90 levels were higher only in the lamina propria of the
tumoral tissue than in tubular adenoma and normal mucosa. In
conclusion, only Hsp60 and Hsp10 levels were found to char-
acterize the adenoma lesions and be also present at high levels
in the fully developed adenocarcinoma. Thus, the presence of
elevated levels of the two chaperonins in adenoma is an indi-
cator of bad prognosis and should help the pathologist make
adequate predictions of disease progression.
Several articles have been published about the Hsps and
cancer (see for example Lianos et al. 2015). High levels of
Hsp10 in the cytoplasm of cancer cells have been reported in
the past (Cappello et al. 2005c). Also, Hsp60 has been shown
to be augmented and localized to the cytoplasm of cancer cells
and its implication in the pathogenesis of a range of human
cancer types has been proposed (Cappello et al. 2005c; Rappa
et al. 2012; Campanella et al. 2015). For example, it has been
reported that Hsp60 promotes tumor cell growth in breast,
lung, and colon cancer, by stabilizing the levels of survivin
and overcoming the apoptotic stimuli (Ghosh et al. 2008). In
another study, the levels of Hsp60 in several cases of gastric
cancer were found elevated and were closely associated with
Fig. 1 Histograms show percentage of cells immunopositive for Hsp10,
Hsp60, Hsp70, and Hsp90 in epithelial cells (EC) (a) and in cells of
lamina propria (LPC) (b) in human large bowel normal mucosa (NM),
tubular adenoma (TA), and adenocarcinoma (AC). Data are presented as
the means ± SD. *p < 0.05
Table 1 Percentages of cells
immunopositive for Hsps in large
bowel mucosa
Immunostaining for: NM TA AC
EC (%) LPC (%) EC (%) LPC (%) EC (%) LPC (%)
Hsp10 48.5 2.1 67.5 6.2 90 10
Hsp60 6 1.9 65 5 95 10
Hsp70 30 3.5 30 3.5 65 5
Hsp90 70 30 75 25 78 40
The immunohistochemical evaluations are expressed as average percentage in epithelial cells (EC) and lamina
propria cells (LPC) in normal mucosa (NM), tubular adenoma (TA), and adenocarcinoma (AC) of human large
bowel (see Materials and Methods for technical details)
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tumor aggressiveness (Li et al. 2014). In contrast, other au-
thors have shown lower levels of Hsp60 in various types of
human cancer (Ito et al. 1998; Lebret et al. 2003; Cappello
et al. 2005a, 2006). Hsp70 and Hsp90 have also been found
Fig. 2 Representative images of
immunohistochemical results for
Hsp10, Hsp60, Hsp70, and
Hsp90 in human large bowel
biopsies of normal mucosa,
tubular adenoma with moderate
grade of dysplasia, and
adenocarcinoma with moderate
grade of differentiation.
Magnification 400×. Scale bar
100 μm. Arrows show the
positivity for the Hsps in the
epithelial cells of normal mucosa.
Note the slight positivity for
Hsp60 in normal epithelial cells
Fig. 3 Tubular adenoma.
Representative high-power
images of immunostaining for
Hsp10 and Hsp60 in lamina
propria cells with the typical
characteristics of inflammatory
cells (arrows). (Magnification
630× and 1000×)
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increased in several types of cancer in which they may pro-
mote the carcinogenic process by inhibiting apoptosis (Beere
2001) and by binding tumor-suppressor proteins, such as p53
and HER2 (Vargas-Roig et al. 1998).
The immunohistochemical study reported here is, to our
knowledge, the first in which a comparative evaluation of
Hsp10, Hsp60, Hsp70, and Hsp90 levels was carried out with
biopsies from tubular adenoma cases taken by us as examples
of large bowel pre-neoplastic lesions. In the literature, there
are several studies on cancer and Hsps in which comparisons
were made but only between normal and neoplastic tissues.
Our results show that among the four Hsps studied, only
Hsp10 and Hsp60 levels are higher in both epithelial and
lamina propria layers of pre-neoplastic as well as in cancer
lesions compared to normal mucosa. Therefore, we hypothe-
size that these molecules are involved in the very early steps of
carcinogenesis in the large bowel. For this reason, Hsp10 and
Hsp60 are not only promising candidates as diagnostic bio-
markers, but they should also be taken into consideration in
the design of therapeutic means aiming at the chaperones.
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